European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma
American Journal of Hematology · 2025-12 · 100 (12) · 2320-2332
DOI: 10.1002/ajh.70070 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 09.09.2025. Verfasst von Sueh-Li Lim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Australian Centre for Blood Diseases Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Multiple myeloma (MM) is an incurable blood cancer characterized by clonal bone marrow plasmacytosis, hypercalcemia, renal failure, anemia, and osteolytic bone disease. Approximately 20% of NDMM patients, not predicted to have high‐risk disease at diagnosis, progress early, despite optimal induction +/− ASCT and lenalidomide maintenance, and are subsequently categorized as functional high‐risk (FHR) disease. Standardized risk‐stratification models incorporate biomarkers of tumor burden, existence of high‐risk cytogenetics, with the presence/absence of plasma cell leukemia/extramedullary disease to attribute high‐risk at diagnosis; however, depth/duration of response to novel agent‐based induction (NA‐IND) as dynamic markers of disease risk have not been defined. However, irrespective of diagnostic risk‐stratification, response to NA‐IND may be the single most effective method of identifying patients whose FHR biology portends an unacceptably short overall survival (OS). In this EMN consensus statement, we define FHR‐MM as disease progression within 18 months of commencement of first‐line therapy in the absence of high‐risk cytogenetics, discuss the underlying disease biology, and strategies to improve outcomes for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Australian Centre for Blood Diseases Monash University, Melbourne, Australia.
- Malignant Haematology, Transplantation and Cellular Therapy Services, the Alfred Hospital Melbourne, Melbourne, Australia.
- Department of Hematology, Oncology and Stem Cell Transplantation, Clinical Cancer Research Group, University of Freiburg, Freiburg, Germany.
- Department of Clinical Therapeutics, Plasma Cell Dyscrasias Unit, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città Della Salute e Della Scienza, Torino, Italy.
- Department of Hematology, Amsterdam UMC, VU University, Amsterdam, the Netherlands.
ORCID-Profile: Sueh-Li Lim, Monika Engelhardt, Evangelos Terpos, Pieter Sonneveld
Zitieren
APA
Lim, S. L., Engelhardt, M., Terpos, E., Gay, F., Van de Donk, N. W. C. J., Einsele, H., Sonneveld, P., Kaiser, M., Boccadoro, M., & Spencer, A. (2025). European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma. American Journal of Hematology, 100(12), 2320-2332. https://doi.org/10.1002/ajh.70070
Vancouver
Lim SL, Engelhardt M, Terpos E, Gay F, Van de Donk NWCJ, Einsele H, et al. European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma. American Journal of Hematology. 2025;100(12):2320-2332. doi:10.1002/ajh.70070
BibTeX
@article{Lim2025,
author = {Lim, Sueh-Li and Engelhardt, Monika and Terpos, Evangelos and Gay, Francesca and Van de Donk, Niels W C J and Einsele, Herman and Sonneveld, Pieter and Kaiser, Martin and Boccadoro, Mario and Spencer, Andrew},
title = {European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {12},
pages = {2320--2332},
doi = {10.1002/ajh.70070}
}
EUVIMED